A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Brief description of study
?The primary purpose of the study is to determine the effectiveness and tolerability of the experimental drug I-MIBG or the experimental drug crizotinib for high risk neuroblastoma (NBL) patients when they are undergoing recommended therapy which include chemotherapy plus surgery, two back-to-back stem cell transplants, radiation therapy, and immunotherapy. Crizotinib is an experimental anticancer drug that has not been approved by the FDA for use in treating high-risk NBL. U.S Food and Drug Administration (FDA) is the health authority that gives approval for new medicines to be prescribed in the United States.
Clinical Study Identifier: s18-01777
ClinicalTrials.gov Identifier: NCT03126916
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
